Cumberland Pharmaceuticals (CPIX) Corporate presentation summary

Strategic transaction and operating focus

• Summer 2026 transaction integrated the commercial products and organization with Apotex’s U.S. branded business; $100M+ received, 75% of expenses eliminated, and clinical pipeline retained.

• Branded medicines, including IV acetadote, Caldolor, Kristalose, Vibativ, Vaprisol, Sancuso and Talicia, joined Apotex’s U.S. portfolio.

• Refocused on late-stage clinical development, led by ifetroban, with a mission to advance therapies for significant unmet medical needs.

Ifetroban and clinical programs

• Ifetroban is a potent, selective thromboxane receptor antagonist; its safety profile spans 30 clinical studies and more than 1,400 subjects.

• DMD cardiomyopathy Phase II study completed with breakthrough results; FDA orphan drug and rare pediatric disease designations and Fast Track designation approved.

• Systemic sclerosis Phase 2a enrollment completed; top-line results reported, with ifetroban well tolerated.

• IPF program has IND clearance and a Phase 2 study underway.

• Cancer metastasis prevention Phase 2a met its safety and tolerability endpoint; fewer metastasis-related deaths in the ifetroban arm than placebo (p=0.037), with a follow-on study in design.

Financial position

• Q3 2026 net revenues were $2.5M, gross profit $1.4M, R&D $2.4M, G&A $7.1M, interest income $1.0M, strategic transaction gain $81.1M and net income $70.2M.

• At Sept. 30, 2026, cash and securities were $81M, total assets $114M, liabilities $42M and equity $72M.